390 related articles for article (PubMed ID: 36240005)
21. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
Chen L; Li D; Guo X; Cheng C; Wei X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
[TBL] [Abstract][Full Text] [Related]
22. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
[TBL] [Abstract][Full Text] [Related]
23. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR
Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670
[TBL] [Abstract][Full Text] [Related]
24. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
Lewis AC; Pope VS; Tea MN; Li M; Nwosu GO; Nguyen TM; Wallington-Beddoe CT; Moretti PAB; Anderson D; Creek DJ; Costabile M; Ali SR; Thompson-Peach CAL; Dredge BK; Bert AG; Goodall GJ; Ekert PG; Brown AL; D'Andrea R; Robinson N; Pitman MR; Thomas D; Ross DM; Gliddon BL; Powell JA; Pitson SM
Blood; 2022 Jun; 139(26):3737-3751. PubMed ID: 35443029
[TBL] [Abstract][Full Text] [Related]
25. An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.
Przedborski M; Sharon D; Cathelin S; Chan S; Kohandel M
PLoS Comput Biol; 2022 Sep; 18(9):e1010439. PubMed ID: 36099249
[TBL] [Abstract][Full Text] [Related]
26. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.
Luedtke DA; Su Y; Ma J; Li X; Buck SA; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Lin H; Taub JW; Ge Y
Signal Transduct Target Ther; 2020 Feb; 5(1):17. PubMed ID: 32296028
[TBL] [Abstract][Full Text] [Related]
28. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax in adult acute myeloid leukemia.
Hu M; Li W; Zhang Y; Liang C; Tan J; Wang Y
Biomed Pharmacother; 2023 Dec; 168():115820. PubMed ID: 37925935
[TBL] [Abstract][Full Text] [Related]
30. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF; Zhu F; Dashevsky O; Mizuno R; Lai JX; Hackett L; Ryan CE; Collins MC; Iorgulescu JB; Guièze R; Penailillo J; Carrasco R; Hwang YC; Muñoz DP; Bouhaddou M; Lim YC; Wu CJ; Allan JN; Furman RR; Goh BC; Pervaiz S; Coppé JP; Mitsiades CS; Davids MS
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37751299
[TBL] [Abstract][Full Text] [Related]
31. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH
Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732
[TBL] [Abstract][Full Text] [Related]
32. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
34. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
35. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
[TBL] [Abstract][Full Text] [Related]
36. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
[TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract][Full Text] [Related]
38. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia.
Lima K; Carvalho MFL; Pereira-Martins DA; Nogueira FL; de Miranda LBL; Nascimento MCD; Cavaglieri RC; Schuringa JJ; Machado-Neto JA; Rego EM
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069220
[TBL] [Abstract][Full Text] [Related]
40. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]